Clinical Trial Update: Duration of IPV Priming and Antibody Decay [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update examining IPV priming duration and antibody decay for poliomyelitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Snippet

Sponsor: Centers for Disease Control and Prevention | Conditions: Poliomyelitis | Phase 4 | Status: COMPLETED